Author

Sho Kawashima

Osaka Medical and Pharmaceutical University

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

Akihiro Hori· 1 shared Akino Emi· 1 shared Fumiyo Ogawa· 1 shared Haruaki NoboriiD· 1 shared Hirofumi SawaiD· 1 shared Hiromitsu Shibayama· 1 shared Hirotaka EbinaiD· 1 shared Hong Wu· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

Akihiro Hori

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Antiviral activity of anisomycin against chikungunya virus

Sho Kawashima, Akino Emi, Fumiyo Ogawa, Shoichi Sakaguchi, Taku Ogawa, Hong Wu, Hirotaka Ebina, Youichi Suzuki, Takashi Nakano

This study identifies anisomycin as a potential antiviral agent against chikungunya virus, showing it inhibits viral replication and reduces disease symptoms in vitro and in vivo through a mechanism distinct from its known functions.

bioRxiv · Jun 19, 2026 · PreprintMicrobiology

Discovery of The Clinical Candidate S-892216: A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19

Yuto Unoh, Keiichiro Hirai, Shota Uehara, Sho Kawashima, Haruaki Nobori, Jun Sato, Hiromitsu Shibayama, Akihiro Hori, Kenji Nakahara, Kana Kurahashi, Masayuki Takamatsu, Shiho Yamamoto, Qianhui Zhang, Miki Tanimura, Reiko Dodo, , Yuki Tachibana

This paper describes the discovery of S-892216, a potent SARS-CoV-2 3CLpro inhibitor with antiviral activity against multiple variants and low cross-resistance to existing drugs.

Journal of Medicinal Chemistry · Jul 5, 2025Peer-reviewedBiochemistry